Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates Read more about Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2015 Read more about Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2015
Bellicum to Present at the Barclays Global Healthcare Conference Read more about Bellicum to Present at the Barclays Global Healthcare Conference
Bellicum to Report Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call and Webcast on March 14, 2016 Read more about Bellicum to Report Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call and Webcast on March 14, 2016
FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant Read more about FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant
Bellicum Pharmaceuticals Announces Submission of BPX-701 and BPX-601 Clinical Trial Protocols for Review by the NIH RAC Read more about Bellicum Pharmaceuticals Announces Submission of BPX-701 and BPX-601 Clinical Trial Protocols for Review by the NIH RAC
Bellicum to be Added to the NASDAQ Biotechnology Index Read more about Bellicum to be Added to the NASDAQ Biotechnology Index
Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy Read more about Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Bellicum Announces Oral Presentation at ASH Showing Improved Potency and Control with CIDeCAR T-Cell Therapies Read more about Bellicum Announces Oral Presentation at ASH Showing Improved Potency and Control with CIDeCAR T-Cell Therapies
Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Demonstrating Disease-Free Outcomes in Patients with Genetic Diseases Read more about Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Demonstrating Disease-Free Outcomes in Patients with Genetic Diseases